#4/B

Rec'd PCT/PTO 12 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 24741-1505

In re patent application of
SIMON, Jan *et al.*

Serial No.: 09/763,794 — Group Art Unit: Unassigned

Filed: July 12, 2001 — Examiner: Unassigned

For: LOW MOLECULAR WEIGHT FRAGMENTS OF HYALURONIC ACID FOR PRODUCING VACCINES

09763794.071201

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§ 1.821 – 1.825

Director of Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In response to the Notification to Comply With Requirements for Applications containing Sequence Disclosures mailed May 14, 2001, please amend the application as follows:

IN THE SPECIFICATION:

Page 18, paragraph 6, line 25: Please amend as follows:

B1

Mice (C57/BL6, female, 6-12 weeks, 60 animals, 5 mice per experimental group, 20 g per mouse) were injected with dendritic cells which had previously been treated with a synthetically prepared protein having a defined amino acid sequence, i.e. a (SIINFEK*L (SEQ ID NO: 1), SIIK*FEKL (SEQ ID NO: 2); * = TNP lysine) peptide. The peptide is selected such that it can react directly with the MHC molecule antigen-binding site on the cell surface of antigen-presenting cells; this means that it is presented on the surface of dendritic cells immediately after they have been added. The hapten trinitrophenyl (TNP), which constitutes the antigenic determinant, is in turn coupled to this peptide. This means that a T cell which is activated by the trinitrophenyl-coupled peptide which is presented by the dendritic cell becomes reactive to trinitrophenyl or chemicals which are structurally homologous to trinitrophenyl, such